{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:20:33Z","timestamp":1785464433908,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Medical University of Lublin","doi-asserted-by":"crossref","award":["DS176"],"award-info":[{"award-number":["DS176"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00277-015-2579-5","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:17:26Z","timestamp":1450743446000},"page":"425-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"95","author":[{"given":"Monika","family":"Podhorecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadiusz","family":"Macheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Chocholska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Bojarska-Junak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Szymczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Goracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dmoszynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"2579_CR1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1999.17.1.399","volume":"17","author":"F Calligaris-Cappio","year":"1999","unstructured":"Calligaris-Cappio F, Hamblin TJ (1999) B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17:399\u2013408","journal-title":"J Clin Oncol"},{"key":"2579_CR2","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin GA, Dumitru CD, Shimizu M et al (2002) Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524\u201315529","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2579_CR3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0268-960X(97)90007-2","volume":"11","author":"TJ Hamblin","year":"1997","unstructured":"Hamblin TJ, Oscier DG (1997) Chronic lymphocytic leukemia: the nature of the leukemic cells. Blood Rev 11:119\u2013122","journal-title":"Blood Rev"},{"key":"2579_CR4","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"2579_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.12703\/P6-65","volume":"6","author":"E Tausch","year":"2014","unstructured":"Tausch E, Mertens D, Stilgenbauer S (2014) Advances in treating chronic lymphocytic leukemia. F1000Prime Rep 6:65\u201372","journal-title":"F1000Prime Rep"},{"key":"2579_CR6","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","volume":"32","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM (2014) Entering the era of targeted for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 32:3039\u20133047","journal-title":"J Clin Oncol"},{"key":"2579_CR7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cam4.226","volume":"3","author":"A Cuneo","year":"2014","unstructured":"Cuneo A, Cavazzini F, Ciccone M et al (2014) Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med 3:555\u2013564","journal-title":"Cancer Med"},{"key":"2579_CR8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-010-0988-z","volume":"89","author":"M Podhorecka","year":"2010","unstructured":"Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszy\u0144ska A (2010) Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol 89:1115\u20131124","journal-title":"Ann Hematol"},{"key":"2579_CR9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00277-010-1045-7","volume":"90","author":"M Podhorecka","year":"2011","unstructured":"Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszy\u0144ska A (2011) Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia. Ann Hematol 90:173\u2013183","journal-title":"Ann Hematol"},{"key":"2579_CR10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM198306093082306","volume":"308","author":"YS Ahn","year":"1983","unstructured":"Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG (1983) Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 308:1396\u20131400","journal-title":"N Engl J Med"},{"key":"2579_CR11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","volume":"116","author":"F Maloisel","year":"2004","unstructured":"Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A et al (2004) Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 116:590\u2013594","journal-title":"Am J Med"},{"key":"2579_CR12","first-page":"136","volume":"4","author":"IN Nakhoul","year":"2006","unstructured":"Nakhoul IN, Kozuch P, Varma M (2006) Management of adult idiopathic thrombocytoia purpura. Clin Adv Hematol Oncol 4:136\u2013144","journal-title":"Clin Adv Hematol Oncol"},{"key":"2579_CR13","first-page":"1130","volume":"4","author":"A Szmydki-Baran","year":"2008","unstructured":"Szmydki-Baran A, Adamowicz-Salach A, Go\u0142\u0119biowska- -Staroszczyk S (2008) Danazol \u2013 skuteczny lek drugiego rzutu w idiopatycznej plamicy ma\u0142op\u0142ytkowej u dzieci. Opis 3 przypadk\u00f3w. Med Wieku Rozwoj 4:1130\u20131134","journal-title":"Med Wieku Rozwoj"},{"key":"2579_CR14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12185-013-1370-4","volume":"98","author":"H Kashiwagi","year":"2013","unstructured":"Kashiwagi H, Tomiyama Y (2013) Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol 98:24\u201333","journal-title":"Int J Hematol"},{"key":"2579_CR15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-102-3-298","volume":"102","author":"YS Ahn","year":"1985","unstructured":"Ahn YS, Harrington WJ, Mylvaganam R, Ayub J, Pall LM (1985) Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 102:298\u2013301","journal-title":"Ann Intern Med"},{"key":"2579_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1179\/102453311X12902908412075","volume":"16","author":"V Fontana","year":"2011","unstructured":"Fontana V, Dudkiewicz P, Ahn ER, Horstman L, Ahn YS (2011) Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD). Hematology 16:90\u201394","journal-title":"Hematology"},{"key":"2579_CR17","first-page":"595","volume":"85","author":"F Cervantes","year":"2000","unstructured":"Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E (2000) Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 85:595\u2013599","journal-title":"Haematologica"},{"key":"2579_CR18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1034\/j.1600-0609.2002.01669.x","volume":"68","author":"G Damaj","year":"2002","unstructured":"Damaj G, Lefrere F, Canioni D et al (2002) Remission of transformed myelodysplastic syndrome with fibrosis after danazol therapy. Eur J Haematol 68:233\u2013235","journal-title":"Eur J Haematol"},{"key":"2579_CR19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/leu.2011.386","volume":"26","author":"S Tung","year":"2012","unstructured":"Tung S, Spaner DE (2012) A role for danazol in chronic lymphocytic leukemia. Leukemia 26:1684\u20131686","journal-title":"Leukemia"},{"key":"2579_CR20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cyto.990130802","volume":"13","author":"Z Darzynkiewicz","year":"1992","unstructured":"Darzynkiewicz Z, Bruno S, Del Bino G et al (1992) Features of apoptotic cells measured by flow cytometry. Cytometry 13:795\u2013808","journal-title":"Cytometry"},{"key":"2579_CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/B978-0-12-385493-3.00004-8","volume":"103","author":"D Wlodkowic","year":"2011","unstructured":"Wlodkowic D, Telford W, Skommer J, Darzynkiewicz Z (2011) Apoptosis and beyond: cytometry in studies of programmed cell death. Methods Cell Biol 103:55\u201398","journal-title":"Methods Cell Biol"},{"key":"2579_CR22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440\u2013446","journal-title":"Cancer Res"},{"key":"2579_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1468-0734.2000.00002.x","volume":"4","author":"E Matutes","year":"2000","unstructured":"Matutes E, Polliack A (2000) Morphological and immunophenotypic features of chronic lymphocytic leukemia. Rev Clin Exp Hematol 4:22\u201347","journal-title":"Rev Clin Exp Hematol"},{"key":"2579_CR24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2354.2004.00489.x","volume":"13","author":"A Redaelli","year":"2004","unstructured":"Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL (2004) The clinical and epidemiological burden of chronic lymphocytic leukemia. Eur J Cancer Care 13:279\u2013287","journal-title":"Eur J Cancer Care"},{"key":"2579_CR25","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0029-7844(99)00635-3","volume":"95","author":"I Matalliotakis","year":"2000","unstructured":"Matalliotakis I, Neonaki M, Koumantaki Y, Goumenou A, Kyriakou D, Koumantakis E (2000) A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. Obstet Gynecol 95:810\u2013813","journal-title":"Obstet Gynecol"},{"key":"2579_CR26","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood-2010-05-285999","volume":"117","author":"J Tomic","year":"2011","unstructured":"Tomic J, Lichty B, Spaner DE (2011) Aberrant interferon-signaling is associated with aggressive CLL. Blood 117:2668\u20132680","journal-title":"Blood"},{"key":"2579_CR27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3892\/ijmm_00000147","volume":"23","author":"T Tanaka","year":"2009","unstructured":"Tanaka T (2009) Danazol regulates the functions of normal human endometrial stromal cell subpopulations by modifying endometrial cytokine networks. Int J Mol Med 23:421\u2013428","journal-title":"Int J Mol Med"},{"key":"2579_CR28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/ijmm_00000147","volume":"23","author":"T Tanaka","year":"2009","unstructured":"Tanaka T, Umesaki N (2009) Danazol enhances Fas-mediated apoptosis in human endometrial epithelial cells within normal physiology. Int J Mol Med 23:237\u2013243","journal-title":"Int J Mol Med"},{"key":"2579_CR29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.pgp.0000130109.80359.57","volume":"23","author":"K Ueki","year":"2004","unstructured":"Ueki K, Kumagai K, Yamashita H, Li ZL, Ueki M, Otsuki Y (2004) Expression of apoptosis-related proteins in adenomyotic uteri treated with danazol and GnRH agonists. Int J Gynecol Pathol 23:248\u2013258","journal-title":"Int J Gynecol Pathol"},{"key":"2579_CR30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1568006033481384","volume":"4","author":"JP Kolb","year":"2003","unstructured":"Kolb JP, Kern C, Quiney C, Roman V, Billard C (2003) Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 4:261\u2013286","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"2579_CR31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.beha.2009.12.002","volume":"23","author":"M Hallek","year":"2010","unstructured":"Hallek M (2010) Therapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 23:85\u201396","journal-title":"Best Pract Res Clin Haematol"},{"key":"2579_CR32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","volume":"9","author":"VA Morrison","year":"2009","unstructured":"Morrison VA (2009) Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 9:365\u2013370","journal-title":"Clin Lymphoma Myeloma"},{"key":"2579_CR33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/sj.leu.2401368","volume":"13","author":"T Robak","year":"1999","unstructured":"Robak T, B\u0142onski JZ, Urbanska-Rys H, B\u0142asi\u0144ska-Morawiec M, Skotnicki AB (1999) 2-Chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 13:518\u2013523","journal-title":"Leukemia"},{"key":"2579_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/asheducation-2010.1.77","volume":"2010","author":"RR Furman","year":"2010","unstructured":"Furman RR (2010) Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:77\u201381","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2579_CR35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/asheducation-2009.1.421","volume":"2009","author":"TD Shanafelt","year":"2009","unstructured":"Shanafelt TD (2009) Predicting clinical outcome in CLL: how and why. Hematology Am Soc Hematol Educ Program 2009:421\u2013429","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2579_CR36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.beha.2009.12.003","volume":"23","author":"T Zenz","year":"2010","unstructured":"Zenz T, Fr\u00f6hling S, Mertens D, D\u00f6hner H, Stilgenbauer S (2010) Moving from prognostic to predictive factors in chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol 23:71\u201384","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2579-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2579-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2579-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T07:14:53Z","timestamp":1589613293000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2579-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2579"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2579-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]}}}